Democratizing cancer risk testing in children before alloHCT
- 25 September 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6564-6566
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Outcomes of germ line testing for children with hematologic malignancies undergoing hematopoietic cell transplantationBlood Advances, 2026
- Insights into germline predisposition to pediatric lymphoid malignanciesLeukemia, 2025
- Germline predispositions to myeloid malignancies: Across the lifespanSeminars in Hematology, 2025
- Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohortsLeukemia, 2024
- Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMTThe Lancet Haematology, 2023
- Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene‐CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT)British Journal of Haematology, 2023
- Risk of cancer in heterozygous relatives of patients with Fanconi anemiaGenetics in Medicine, 2022
- The clinical and functional effects of TERT variants in myelodysplastic syndromeBlood, 2021
- Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromesHaematologica, 2020